Arch Iran Med. 2018;21(4):158-163.
PMID: 29693406
  Abstract View: 457
  PDF Download: 419

Original Article

Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy for Management of Peritoneal Carcinomatosis 

Saman Nikeghbalian 1, Hamed Nikoupour 1, Masoud Dehghani 1, Mohammad Yasin Karami 2 * , Rahim Hemati 1

1 Shiraz Organ Transplantation Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Student Research Committee, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Cardiac Surgery, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
*Corresponding Author: Mohammad Yasin Karami, MD; Shiraz Organ Transplantation Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. Telefax: +98-713- 626-3054, Email: Email: karamiy@sums.ac.ir

Abstract

Background: Treatment of peritoneal metastases has gained interest among oncologic communities around the world. Cytoreductive surgery (CRS) and hyperthermic intraoperative chemotherapy (HIPEC) have come to be the treatment of choice for selected patients with peritoneal carcinomatosis (PC) in recent years. Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. We reviewed our first 30 patients who underwent CRS and HIPEC. The aim of the study was assessment of the patients’ survival, morbidity, and mortality rate and identifying prognostic factors of patients treated with CRS and HIPEC.

Methods: In this cross-sectional study, data were retrospectively collected from 45 patients (15 men and 30 women) who underwent CRS and HIPEC between December 2008 and October 2016, at Nemaazi educational hospital and Shiraz central hospital of Shiraz University of Medical Sciences. Peri-operative and regular follow-up data on survival and complications were gathered and analyzed to identify their prognostic value for survival.

Results: The mean age of the patients was 49.7±16.46 years. The participants in this study consisted of 19 females (63.3%) and 11 males (36.7%). The most common primary tumor was ovarian cancer (30.1%). A completeness of cytoreduction score of CC0/CC1 was obtained in 80% of patients operated on with curative intent. The overall mortality rate was 20%. The 1- and 4-year overall survival (OS) were 89% and 54%, respectively.

Conclusion: CRS and HIPEC are most successful in treatment of selected patients. Development of complete resection with CRS in these 8 years and good OS in our patients encourage us to continue the procedure with all its difficulties and cost.

Cite this article as: Nikeghbalian S, Nikoupour H, Dehghani M, Karami MY, Hemati R. Cytoreductive surgery and hyperthermic intraoperative chemotherapy for management of peritoneal carcinomatosis. Arch Iran Med. 2018;21(4):158–163.
First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 457

Your browser does not support the canvas element.


PDF Downloaded: 419

Your browser does not support the canvas element.

Submitted: 27 Apr 2017
Accepted: 11 Dec 2017
First published online: 01 Apr 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)